Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics

丹纳赫与阿斯利康达成合作伙伴关系，以扩大精准医疗的规模，包括开发下一代人工智能驱动的诊断技术。

This partnership aims to create a framework for rapid diagnostics research, development and commercialization

该合作伙伴关系旨在为快速诊断研究、开发和商业化创建一个框架。

Danaher, through its Centers for Enabling Precision Medicine, will provide support in all aspects of the development cycle across diagnostic modalities

丹纳赫通过其精准医疗中心，将为诊断模式开发周期的各个方面提供支持。

WASHINGTON

华盛顿

,

，

May 29, 2025

2025年5月29日

/PRNewswire/ -- Danaher Corporation (NYSE:

/PRNewswire/ -- 丹纳赫公司 (纽约证券交易所代码：

DHR

人力资源部

) ('Danaher'), a global science and technology innovator, announced today the launch of a partnership with AstraZeneca (LSE/STO/Nasdaq:

）（'丹纳赫'），全球科学与技术革新者，今天宣布与阿斯利康（LSE/STO/Nasdaq：

AZN

阿塞拜疆新纳兹夫（AZN）

) to develop and commercialize novel diagnostic tools and tests intended to help clinicians better determine which patients would most benefit from precision medicine treatments.

）开发和商业化新型诊断工具和测试，旨在帮助临床医生更好地确定哪些患者最能从精准医疗中获益。

'Precision medicines are more targeted than standard therapies and thus require precision diagnostics to determine which patients are most likely to benefit,' said

“精准药物比标准疗法更有针对性，因此需要精准诊断来确定哪些患者最有可能受益，”

Julie Sawyer Montgomery

朱莉·索耶·蒙哥马利

, Danaher Executive Vice President. 'We are excited to work with AstraZeneca on the goal of creating novel tests to increase access to precision medicines, helping ensure that no patients are left behind.'

丹纳赫执行副总裁表示：“我们很高兴与阿斯利康合作，致力于开发创新检测方法以增加精准医疗的可及性，确保没有任何患者被遗漏。”

This partnership will utilize the newly opened

该合作伙伴关系将利用新开通的

Danaher Centers

丹纳赫中心

for Enabling Precision Medicine to support a more streamlined, end-to-end development process. The first product intended to be developed through this partnership will leverage technologies from Leica Biosystems, one of Danaher's subsidiaries. The initial focus will be on digital and computational pathology products and AI-assisted algorithms, to help clinicians better diagnose patients by identifying those who are most likely to benefit from targeted therapies..

为了推动精准医疗的发展，支持更加精简的端到端开发流程。通过这一合作开发的首款产品将利用丹纳赫旗下子公司徕卡生物系统的技术。初期重点将放在数字与计算病理学产品以及人工智能辅助算法上，以帮助临床医生通过识别最有可能从靶向治疗中受益的患者来更好地进行诊断。

'The transformative potential of next-wave precision medicines such as antibody-drug conjugates will depend on our ability to identify the patients most likely to benefit from them,' said

“下一代精准药物（如抗体药物偶联物）的变革潜力将取决于我们识别最有可能从中受益的患者的能力，”他表示。

Susan Galbraith

苏珊·加尔布雷思

, Executive Vice President, Oncology Haematology R&D, AstraZeneca. 'Our partnership with Danaher and Leica Biosystems underscores our commitment to pioneering AI-based diagnostics which can improve patient selection, and our belief that collaboration is a critical accelerant for such progress.'

阿斯利康肿瘤血液学研发执行副总裁。 “我们与丹纳赫和徕卡生物系统公司的合作，彰显了我们对开创基于人工智能的诊断方法的承诺，这可以改善患者选择，并且我们相信合作是推动此类进展的关键加速器。”

Leica Biosystems has developed leading digital pathology solutions and intends to scale these for use in clinical settings across its footprint of laboratories around the world. To accelerate this digital transformation, the company recently

徕卡生物系统公司已经开发了领先的数字病理学解决方案，并打算在其遍布全球的实验室中扩大这些解决方案在临床环境中的应用。为了加速这一数字化转型，该公司最近

shared its commitment

分享了其承诺

to an open-access Digital Imaging and Communications in Medicine (DICOM) standard, encouraging interoperability for enhanced workflow connectivity.

转向开放式访问的医学数字成像和通信（DICOM）标准，鼓励互操作性以增强工作流程的连通性。

'At Leica Biosystems, we've been driving the new era of digital pathology, where assays that used to be analyzed by the human eye are now also analyzed by digital tools, helping to improve diagnostic accuracy and therapeutic guidance,' said

“在徕卡生物系统公司，我们一直在推动数字病理学的新时代，过去通过人眼分析的检测现在也可以通过数字工具进行分析，有助于提高诊断准确性和治疗指导，”

Gustavo Perez-Fernandez

古斯塔沃·佩雷斯-费尔南德斯

, President of Leica Biosystems. 'With our global footprint and leading digital pathology platform, we expect to be able to deploy the tests developed with AstraZeneca to patients worldwide, which could significantly advance precision medicine and improve outcomes for patients on a global scale.'

徕卡生物系统公司总裁表示：“凭借我们的全球业务和领先的数字病理学平台，我们预计将能够在全球范围内推广与阿斯利康共同开发的测试，这将极大地推动精准医疗的发展，并在全球范围内改善患者的治疗效果。”

ABOUT DANAHER

关于丹纳赫

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies.

丹纳赫是全球领先的生命科学和诊断创新企业，致力于加速推进科学技术的力量以改善人类健康。我们的业务与客户紧密合作，共同解决影响全球患者的一些最重要的健康挑战。丹纳赫的先进科学技术以及经过验证的创新能力，有助于实现更快、更准确的诊断，并帮助减少可持续发现、开发和交付改变生命疗法所需的时间和成本。

Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at .

专注于科学卓越、创新和持续改进，我们遍布全球的大约63,000名员工助力确保丹纳赫正在改善亿万人的生活质量，同时为更健康、更可持续的未来奠定基础。欲了解更多信息，请访问。

www.danaher.com

www.danaher.com

.

。

FORWARD-LOOKING STATEMENTS

前瞻性声明

Statements in this release that are not strictly historical, including any statements of Danaher or any of its direct or indirect subsidiaries regarding events or developments that we believe or anticipate will or may occur in the future are 'forward-looking' statements within the meaning of the federal securities laws.

本发布中的非严格历史性的声明，包括丹纳赫或其任何直接或间接子公司关于我们认为或预期将在未来发生或可能发生的事件或发展的任何声明，均属于联邦证券法意义上的“前瞻性”声明。

There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of tariffs and related actions recently implemented by the U.S.

有许多重要因素可能导致实际结果、发展和商业决策与这些前瞻性陈述所建议或指示的内容存在重大差异，您不应过度依赖任何此类前瞻性陈述。这些因素包括但不限于：美国近期实施的关税及相关措施的影响。

and other countries, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the healthcare industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other cha.

及其他国家，我们的债务义务对运营和流动性的影响，全球经济、我们所服务的市场及金融市场的恶化或不稳定，关于我们业务和产品中人工智能开发、部署和使用的不确定性，全球健康危机的影响，与国家法律或政策相关的不确定性，包括保护或促进国内利益及应对外国竞争的法律或政策，我们所服务市场的收缩、增长率及其周期性，竞争，我们开发并成功推广新产品和技术以及拓展新市场的能力，我们员工、代理或业务合作伙伴不当行为的潜在风险，我们遵守适用法律法规的情况（包括与标签外营销相关的规定及其他与医疗器械和医疗行业相关的法规），我们的临床试验结果及其认知，我们有效应对成本削减和其他变化的能力。

SOURCE Danaher Corporation

来源：丹纳赫公司

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用